CY1115116T1 - Συνδυαστικη θεραπεια για χαπ - Google Patents

Συνδυαστικη θεραπεια για χαπ

Info

Publication number
CY1115116T1
CY1115116T1 CY20141100382T CY141100382T CY1115116T1 CY 1115116 T1 CY1115116 T1 CY 1115116T1 CY 20141100382 T CY20141100382 T CY 20141100382T CY 141100382 T CY141100382 T CY 141100382T CY 1115116 T1 CY1115116 T1 CY 1115116T1
Authority
CY
Cyprus
Prior art keywords
copper
formoterol
treatment
component
composition further
Prior art date
Application number
CY20141100382T
Other languages
English (en)
Inventor
Sauro Bonelli
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42107420&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115116(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of CY1115116T1 publication Critical patent/CY1115116T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/003—Adding propellants in fluid form to aerosol containers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B7/00—Closing containers or receptacles after filling
    • B65B7/16—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons
    • B65B7/28—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
    • B65B7/2842—Securing closures on containers
    • B65B7/285—Securing closures on containers by deformation of the closure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)

Abstract

Η εφεύρεση αφορά μία σύνθεση αερολύματος, κατάλληλη για χορήγηση σε ασθενείς οι οποίοι πάσχουν από ΧΑΠ, μέσω ενός εισπνευστήρα δοσιμετρημένης δόσης υπό πίεση (pMDI), η οποία περιλαμβάνει βρωμιούχο γλυκοπυρρόνιο σε συνδυασμό με φορμοτερόλη. Η σύνθεση επιπλέον περιλαμβάνει ένα προωθητικό μέσο HFA, έναν συν-διαλύτη και μία ποσότητα ανόργανου οξέος, επαρκή να σταθεροποιεί και το συστατικό βρωμιούχο γλυκοπυρρόνιο και το συστατικό φορμοτερόλη. Ενδεχομένως, η σύνθεση επιπλέον περιλαμβάνει διπροπιονική βεκλομεθαζόνη.
CY20141100382T 2009-12-23 2014-05-29 Συνδυαστικη θεραπεια για χαπ CY1115116T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09180671 2009-12-23
EP10799030.1A EP2515855B3 (en) 2009-12-23 2010-12-22 Combination therapy for COPD

Publications (1)

Publication Number Publication Date
CY1115116T1 true CY1115116T1 (el) 2016-12-14

Family

ID=42107420

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100382T CY1115116T1 (el) 2009-12-23 2014-05-29 Συνδυαστικη θεραπεια για χαπ
CY2017047C CY2017047I2 (el) 2009-12-23 2017-12-22 Συνδυαστικη θεραπεια για χαπ

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2017047C CY2017047I2 (el) 2009-12-23 2017-12-22 Συνδυαστικη θεραπεια για χαπ

Country Status (39)

Country Link
US (3) US20110150782A1 (el)
EP (1) EP2515855B3 (el)
JP (2) JP5914354B2 (el)
KR (2) KR101757951B1 (el)
CN (2) CN102665679B (el)
AR (2) AR079726A1 (el)
AU (3) AU2010334859A1 (el)
BR (1) BR112012015337B8 (el)
CA (1) CA2785321C (el)
CL (1) CL2012001705A1 (el)
CO (1) CO6541628A2 (el)
CY (2) CY1115116T1 (el)
DK (1) DK2515855T6 (el)
EA (2) EA021917B1 (el)
ES (1) ES2468840T7 (el)
FI (1) FI2515855T6 (el)
GE (1) GEP20156311B (el)
HK (2) HK1174566A1 (el)
HR (1) HRP20140582T4 (el)
HU (1) HUS1800001I1 (el)
IL (1) IL260932B (el)
LT (1) LTC2515855I2 (el)
LU (1) LUC00060I2 (el)
MA (1) MA33823B1 (el)
MX (1) MX2012006878A (el)
MY (1) MY156949A (el)
NL (1) NL300923I2 (el)
NZ (1) NZ600790A (el)
PE (2) PE20121396A1 (el)
PL (1) PL2515855T6 (el)
PT (1) PT2515855E (el)
RS (1) RS53391B2 (el)
SG (1) SG181868A1 (el)
SI (1) SI2515855T1 (el)
TN (1) TN2012000269A1 (el)
TW (1) TWI495468B (el)
UA (1) UA113832C2 (el)
WO (1) WO2011076843A2 (el)
ZA (1) ZA201204615B (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI495468B (zh) * 2009-12-23 2015-08-11 Chiesi Farma Spa 治療慢性阻塞性肺病（ｃｏｐｄ）之醫藥組成物
GEP20166479B (en) 2009-12-23 2016-05-25 Chiesi Farma Spa Aerosol formulation for copd
ES2468835T3 (es) * 2009-12-23 2014-06-17 Chiesi Farmaceutici S.P.A. Terapia combinada para EPOC
EP2749284A3 (en) * 2011-02-17 2014-08-20 Cipla Limited Combination of glycopyrronium and carmoterol
DK2765994T3 (en) * 2011-10-11 2019-03-04 Chiesi Farm Spa Crystalline microparticles of a beta agonist coated with a fatty acid
CA2885767A1 (en) * 2012-10-23 2014-05-01 Cipla Limited Pharmaceutical composition
DK3409270T3 (da) 2013-07-11 2021-04-26 Chiesi Farm Spa Tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum til indgivelse ved inhalation
MX368835B (es) * 2013-12-30 2019-10-18 Chiesi Farm Spa Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol.
HUE039359T2 (hu) * 2013-12-30 2018-12-28 Chiesi Farm Spa Glikopirrónium-bromid és formoterol kombináció stabil, túlnyomásos aeroszol oldat készítménye
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
GB201416909D0 (en) * 2014-09-25 2014-11-12 Prosonix Ltd Method of forming concentrated solution
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
TWI731891B (zh) 2015-11-16 2021-07-01 義大利商吉斯藥品公司 含有抗膽鹼劑、皮質類固醇及β-腎上腺素之乾粉配方之製備方法
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3436115B1 (en) 2016-03-31 2021-07-28 Chiesi Farmaceutici S.p.A. Aerosol inhalation device
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
BR112019005168A2 (pt) 2016-09-19 2019-06-11 Mexichem Fluor Sa De Cv composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível de sofrer de um distúrbio respiratório, para melhoria da estabilidade de uma composição farmacêutica e do desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica
CN114272238A (zh) 2016-09-19 2022-04-05 墨西哥氟石股份公司 药物组合物
WO2018051132A1 (en) * 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
RU2742376C1 (ru) * 2017-05-11 2021-02-05 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик
PL3621589T3 (pl) 2017-05-11 2021-12-06 Chiesi Farmaceutici S.P.A. Sposób wytwarzania preparatu suchego proszku obejmującego środek antycholinergiczny, kortykosteroid i środek beta-adrenergiczny
AU2019477296A1 (en) 2019-12-02 2022-04-14 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers
AU2021314977A1 (en) 2020-07-31 2023-03-02 Chemo Research, S.L. Combination therapy for inhalation administration
CA3193038A1 (en) 2020-10-09 2022-04-14 Enrico Zambelli A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227781A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227783A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227782A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
SG52459A1 (en) * 1992-12-09 1998-09-28 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
JP4570251B2 (ja) 1998-07-24 2010-10-27 ヤゴテック アーゲー 医薬用エーロゾル製剤
NZ509489A (en) * 1998-08-04 2002-10-25 Jago Res A Medicinal aerosol formulations comprising cromoglycic acid and/or nedocromil
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
EA005179B1 (ru) * 2000-05-22 2004-12-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Стабильные фармацевтические препараты в виде растворов для дозированных ингаляторов под давлением
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
PL207377B1 (pl) 2001-03-30 2010-12-31 Jagotec Ag Medyczny preparat aerozolowy, sposób wytwarzania medycznego preparatu aerozolowego oraz zastosowanie soli kwasów karboksylowych jako środków pomocniczych w tym preparacie
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
NZ535018A (en) 2002-03-01 2007-02-23 Chiesi Farmaceutici S Pharmaceutical aerosol formulation containing formoterol, and its method of production
EP1575588A1 (en) 2002-12-16 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG Tiotropium containing hfc solution formulations
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
NZ548302A (en) * 2004-02-06 2010-04-30 Meda Pharma Gmbh & Co Kg Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
CN100569235C (zh) 2004-02-06 2009-12-16 Meda制药有限及两合公司 用于哮喘和copd长期治疗的抗胆碱能药和糖皮质激素的组合
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1616567A1 (en) 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
GB0505545D0 (en) 2005-03-17 2005-04-27 Glaxo Group Ltd Inhalation devices
JP2008534611A (ja) 2005-03-30 2008-08-28 シェーリング コーポレイション 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
AU2006276343B2 (en) 2005-08-01 2009-10-08 Astrazeneca Ab Inhaler valve
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
DE602006008665D1 (de) * 2005-12-21 2009-10-01 Meda Pharma Gmbh & Co Kg Kombination von r,r-glycopyrrolat, rolipram und budesonid zur behandlung von entzündungskrankheiten
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
ES2969237T3 (es) 2007-10-18 2024-05-17 Rose U Llc Formulaciones tópicas de glicopirrolato y una toallita que contiene las mismas
EP2440196A4 (en) * 2009-06-09 2013-01-02 Elevation Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTRATION OF BETA 2 NEBULIZED AGONIST OR A COMBINATION OF BETA 2 NEBULIZED AGONIST AND ANTICHOLINERGIC
KR101795348B1 (ko) * 2009-12-23 2017-12-01 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 에어로졸 제제
ES2468835T3 (es) 2009-12-23 2014-06-17 Chiesi Farmaceutici S.P.A. Terapia combinada para EPOC
GEP20166479B (en) * 2009-12-23 2016-05-25 Chiesi Farma Spa Aerosol formulation for copd
TWI495468B (zh) * 2009-12-23 2015-08-11 Chiesi Farma Spa 治療慢性阻塞性肺病（ｃｏｐｄ）之醫藥組成物
DK3409270T3 (da) * 2013-07-11 2021-04-26 Chiesi Farm Spa Tørpulverformulering omfattende et antikolinergikum, et corticosteroid og et beta-adrenergikum til indgivelse ved inhalation
MX368835B (es) * 2013-12-30 2019-10-18 Chiesi Farm Spa Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol.
HUE039359T2 (hu) 2013-12-30 2018-12-28 Chiesi Farm Spa Glikopirrónium-bromid és formoterol kombináció stabil, túlnyomásos aeroszol oldat készítménye
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Also Published As

Publication number Publication date
AU2016234895A1 (en) 2016-10-13
NL300923I2 (en) 2019-07-22
CA2785321A1 (en) 2011-06-30
DK2515855T3 (da) 2014-06-30
JP2013515696A (ja) 2013-05-09
AU2018202998A1 (en) 2018-05-17
EA027778B1 (ru) 2017-08-31
BR112012015337B8 (pt) 2021-05-25
MY156949A (en) 2016-04-15
PL2515855T3 (pl) 2014-08-29
CL2012001705A1 (es) 2012-09-28
CN102665679A (zh) 2012-09-12
RS53391B (en) 2014-10-31
CN104055765A (zh) 2014-09-24
HK1197036A1 (en) 2015-01-02
PE20160853A1 (es) 2016-09-14
HRP20140582T1 (hr) 2014-08-01
NL300923I1 (en) 2018-01-17
WO2011076843A3 (en) 2011-12-01
JP6283388B2 (ja) 2018-02-21
ES2468840T7 (es) 2023-11-29
HRP20140582T4 (hr) 2023-06-09
GEP20156311B (en) 2015-07-10
CY2017047I1 (el) 2018-04-04
BR112012015337B1 (pt) 2021-05-04
CY2017047I2 (el) 2018-04-04
PL2515855T6 (pl) 2023-12-18
CN104055765B (zh) 2016-11-23
TN2012000269A1 (en) 2013-12-12
AU2010334859A1 (en) 2012-07-12
UA113832C2 (xx) 2017-03-27
AR115897A2 (es) 2021-03-10
BR112012015337A2 (pt) 2016-03-15
CN102665679B (zh) 2014-11-26
AR079726A1 (es) 2012-02-15
LUC00060I1 (el) 2018-01-18
SG181868A1 (en) 2012-07-30
TWI495468B (zh) 2015-08-11
AU2016234895B2 (en) 2018-02-01
EP2515855A2 (en) 2012-10-31
US11389401B2 (en) 2022-07-19
ZA201204615B (en) 2013-09-25
WO2011076843A2 (en) 2011-06-30
EP2515855B3 (en) 2023-05-03
IL260932B (en) 2021-04-29
PT2515855E (pt) 2014-06-11
EP2515855B1 (en) 2014-04-02
JP5914354B2 (ja) 2016-05-11
PE20121396A1 (es) 2012-10-24
RS53391B2 (sr) 2023-09-29
HK1174566A1 (en) 2013-06-14
US20190046433A1 (en) 2019-02-14
FI2515855T6 (fi) 2023-06-02
MA33823B1 (fr) 2012-12-03
LTPA2018001I1 (lt) 2018-02-12
KR101757951B1 (ko) 2017-07-13
LUC00060I2 (el) 2018-03-16
US20150328144A1 (en) 2015-11-19
US20110150782A1 (en) 2011-06-23
DK2515855T6 (da) 2023-06-06
JP2016145239A (ja) 2016-08-12
US10159645B2 (en) 2018-12-25
CA2785321C (en) 2018-08-21
LTC2515855I2 (lt) 2019-05-10
TW201129359A (en) 2011-09-01
EA021917B1 (ru) 2015-09-30
MX2012006878A (es) 2012-07-04
EA201590179A1 (ru) 2015-09-30
HUS1800001I1 (hu) 2018-02-28
KR20120103653A (ko) 2012-09-19
SI2515855T1 (sl) 2014-08-29
EA201290375A1 (ru) 2013-01-30
NZ600790A (en) 2014-09-26
KR20170040392A (ko) 2017-04-12
CO6541628A2 (es) 2012-10-16
ES2468840T3 (es) 2014-06-17

Similar Documents

Publication Publication Date Title
CY1115116T1 (el) Συνδυαστικη θεραπεια για χαπ
WO2011076841A3 (en) Combination therapy for copd
CY1115109T1 (el) Συνθεση αερολυματος για χαπ
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
WO2012110770A3 (en) Combination of glycopyrrolate and a beta2 -agonist
CY1123918T1 (el) Βελτιωμενα σκευασματα
CY1117568T1 (el) Χρηση μιας συνθεσης η οποια περιλαμβανει φορμοτερολη και διπροπιονικη βεκλομεθαζονη για την αγωγη μιας εξαρσης ασθματος
PH12019500315A1 (en) Combination therapy for copd
CY1118499T1 (el) Χρηση ενος αναστολεα αρωματασης για την αντιμετωπιση υπογοναδισμου και σχετικων νοσων
CY1115266T1 (el) Φαρμακευτικες συνθεσεις αερολυματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
CR11439A (es) Composiciones para inhalacion comprendiendo acido montelukast y un inhibidor pde-4 o un corticosteroide inhalado
UY34496A (es) Formulacion nasal
TH127043A (th) ผลิตภัณฑ์รวมสำหรับบำบัด copd
TH127043B (th) ผลิตภัณฑ์รวมสำหรับบำบัด copd
BR102012008322B8 (pt) formulações medicinais em aerossol que não debilitam a camada de ozônio e com baixo efeito estufa
CY1114013T1 (el) Ο συνδυασμος αντιχολινεργικων και γλυκοκορτικοειδων για την μακροχρονια θεραπεια του ασθματος και της χαπ
CY1118684T1 (el) Διαδερμικα επιθεματα χαμηλης δοσης με υψηλη απελευθερωση φαρμακου
DOP2010000305A (es) Metodo y composicion farmaceutica para lograr niveles plasmaticos de progesterona requeridos para diferentes indicaciones terapeuticas
TH131144A (th) สูตรผสมแอโรโซลสำหรับ copd
TH131144B (th) สูตรผสมแอโรโซลสำหรับ copd
CO6311072A2 (es) Composición farmacéutica inyectable de progesterona